Lack of Effect of Antioxidants on Biopharmaceutics Classification System (BCS) Class III Drug Permeability

被引:1
|
作者
Yu, Yuly Chiang [1 ]
Lu, Dongmei [2 ]
Rege, Bhagwant [2 ]
Polli, James E. [1 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[2] FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
Permeation; Absorption; Dissolution; Caco-2; MDCK-II; Biopharmaceutics Classification System; Antioxidants; Nitrosamine; Excipients; ORAL DOSAGE FORMS; BIOWAIVER MONOGRAPHS; PASSIVE PERMEABILITY; COMMON EXCIPIENTS; IN-VITRO; ACID; PHARMACEUTICALS; NITROSAMINES; PIRENZEPINE; DISSOLUTION;
D O I
10.1016/j.xphs.2024.03.005
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The addition of antioxidants to pharmaceutical products is a potential approach to inhibit nitrosamine formation, particularly in solid oral dosage forms like tablets and capsules. The objective was to assess the effect of ten antioxidants on the permeability of four Biopharmaceutics Classification System (BCS) Class III drugs. Bidirectional drug permeability studies in the absence and presence of antioxidants were performed in vitro across MDCK-II monolayers. No antioxidant increased drug permeability, while the positive control sodium lauryl sulfate always increased drug permeability. Results support that any of the ten antioxidants, up to at least 10 mg, can be added to a solid oral dosage form without modulating passive drug intestinal permeability. Additional considerations are also discussed. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:2215 / 2222
页数:8
相关论文
共 50 条
  • [1] The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development
    Benet, Leslie Z.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (01) : 34 - 42
  • [2] The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines
    Charalabidis, Aggelos
    Sfouni, Maria
    Bergstrom, Christel
    Macheras, Panos
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 566 : 264 - 281
  • [3] The biopharmaceutics classification system (BCS): Class III drugs - better candidates for BA/BE waiver?
    Blume, HH
    Schug, BS
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 9 (02) : 117 - 121
  • [4] Possibility of extending biopharmaceutics classification system based biowaiver to BCS class Ha drug
    Khalid, Farah
    Hassan, Syed Muhammad Farid
    Noor, Rabia
    Zaheer, Kamran
    Hassan, Fouzia
    Muhammad, Iyad Naeem
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 32 (05) : 2065 - 2073
  • [5] Optimizing Solubility and Permeability of a Biopharmaceutics Classification System (BCS) Class 4 Antibiotic Drug Using Lipophilic Fragments Disturbing the Crystal Lattice
    Tehler, Ulrika
    Fagerberg, Jonas H.
    Svensson, Richard
    Larhed, Mats
    Artursson, Per
    Bergstrom, Christel A. S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (06) : 2690 - 2694
  • [6] Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug ProductsCimetidine
    Ekarat Jantratid
    Sompol Prakongpan
    Gordon L. Amidon
    Jennifer B. Dressman
    Clinical Pharmacokinetics, 2006, 45 : 385 - 399
  • [7] Drug Permeability-Best Practices for Biopharmaceutics Classification System (BCS)-Based Biowaivers: A workshop Summary Report
    Mehta, M.
    Polli, J. E.
    Seo, P.
    Bhoopathy, S.
    Berginc, K.
    Kristan, K.
    Cook, J.
    Dressman, J. B.
    Mandula, H.
    Munshi, U.
    Shanker, R.
    Volpe, D. A.
    Gordon, J.
    Veerasingham, S.
    Welink, J.
    Almeida, S.
    Gonzalez, P.
    Painter, D.
    Tsang, Y. C.
    Vaidyanathan, J.
    Velagapudi, R.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (07) : 1749 - 1762
  • [8] Feasibility of biowaiver extension to Biopharmaceutics Classification System Class III drug products - Cimetidine
    Jantratid, E
    Prakongpan, S
    Amidon, GL
    Dressman, JB
    CLINICAL PHARMACOKINETICS, 2006, 45 (04) : 385 - 399
  • [9] Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS)
    Fagerholm, Urban
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (06) : 751 - 757
  • [10] The biopharmaceutics classification system (BCS) differences matter in be determination?
    Amidon, Gordon L.
    Walgreen, Charles R., Jr.
    DRUG METABOLISM REVIEWS, 2006, 38 : 29 - 29